Come up with a name for your new list and we'll add to it:
Aeolus Pharmaceuticals raised a round of funding on August 19, 2010. Investors include
Xmark Opportunity Partners.
Aeolus is developing a variety of therapeutic agents based on its proprietary small molecule catalytic antioxidants, with AEOL 10150 being the first to enter human clinical evaluation. AEOL 10150 is a…